Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-09-26T00:15:48.312Z.
Consensus retrieved: 2026-09-13T22:56:00.612Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-09-26T00:15:48.312Z.
Quote observation: 2026-09-25T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d53bd5f3ae2a50c36c12dad7416524538d3c4f55d98f345e848307cf0610ae84
FORWARD PE RATIO
N/A
GSK plc
Market Cap
$98.65B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| GSK plc (GSK) | $98.65B | N/A |
| Sanofi (SNY)vs › | $98.71B | N/A |
| McKesson Corporation (MCK)vs › | $101.46B | 19.42 |
| HCA Healthcare, Inc. (HCA)vs › | $94.31B | 14.78 |
| Stryker Corporation (SYK)vs › | $104.41B | 18.14 |
| Elevance Health Inc. (ELV)vs › | $85.90B | 14.59 |
| Medtronic plc (MDT)vs › | $113.46B | 14.84 |
| CVS Health Corp. (CVS)vs › | $113.72B | 11.14 |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $81.19B | 14.46 |
| Moderna, Inc. (MRNA)vs › | $78.91B | N/A |
Trailing P/E
15.6
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
Consensus estimates for this stock are reported in GBP, while the share price trades in USD — so per-fiscal-year implied multiples can't be computed honestly here. The analyst estimates table shows the consensus figures with their correct currency label.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
